The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
The multifaceted role of autophagy in cancer and the microenvironment
Open accessAbstract
Autophagy is a crucial recycling process that is increasingly being recognized as an important factor in cancer initiation, cancer (stem) cell maintenance as well as the development of resistance to cancer therapy in both solid and hematological malignancies. Furthermore, it is being recognized that autophagy also plays a crucial and sometimes opposing role in the complex cancer microenvironment. For instance, autophagy in stromal cells such as fibroblasts contributes to tumorigenesis by generating and supplying nutrients to cancerous cells. Reversely, autophagy in immune cells appears to contribute to tumor‐localized immune responses and among others regulates antigen presentation to and by immune cells. Autophagy also directly regulates T and natural killer cell activity and is required for mounting T‐cell memory responses. Thus, within the tumor microenvironment autophagy has a multifaceted role that, depending on the context, may help drive tumorigenesis or may help to support anticancer immune responses. This multifaceted role should be taken into account when designing autophagy‐based cancer therapeutics. In this review, we provide an overview of the diverse facets of autophagy in cancer cells and nonmalignant cells in the cancer microenvironment. Second, we will attempt to integrate and provide a unified view of how these various aspects can be therapeutically exploited for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150 · cited 1×
“Cancer cells typically metabolize glucose to lactate, even when sufficient oxygen is present to support oxidative phosphorylation, a phenomenon known as the Warburg effect.(140) Of note, pyruvate kinase (PKM2) is the final enzyme in the glycolytic pathway that controls the glycolytic flux and is therefore important fo…”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“In this respect, encapsulation of chemotherapeutic drugs such as doxorubicin in liposomes has yielded more effective formulations with less side effects.(334) Such formulations can be further optimized by using antibody‐ conjugated and tumor‐targeted liposomes.”
BackgroundPankiv, S., Clausen, T. H., Lamark, T., Brech, A., Bruun, J.-A., Outzen, H., Øvervatn, A., Bjørkøy, G., & Johansen, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702824200 · Cited by 4,578 · cited 3×
“167,168 This sensitizing effect of autophagy inhibition was abolished in cells lacking PUMA, indicating that FOXO3a‐ dependent mechanism induction of PUMA contributes to drug resistance.167 Interestingly, an important regulator of initiator caspase‐8 activation, the antiapoptotic protein FLIP, also can regulate autoph…”
BackgroundRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506
Induction of autophagy and inhibition of tumorigenesis by beclin 1
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., & Levine, B. (1999) · Nature · doi:10.1038/45257 · Cited by 3,347
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“of calreticulin to the cell surface and the release of several immune‐stimulating factors, among which HMGB1 and ATP.(258,259) During ICD, depletion of ATG5 or ATG7 in CT26 murine colon cancer cells or knockdown of Beclin‐1 reduced ATP‐release upon anthracycline treatment and inhibited in vivo anticancer immunity.”
Background
Cited by
The interplay of ROS and the PI3K/Akt pathway in autophagy regulation
Kma, L., & Baruah, T. J. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2104 · Cited by 394
The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer
Yan, Y., Chen, X., Wang, X., Zhao, Z., Hu, W., Zeng, S., Wei, J., Yang, X., Qian, L., Zhou, S., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1172-5 · Cited by 113
Metadata
- Authors
- Folkerts, H., Hilgendorf, S., Vellenga, E., Bremer, E., & Wiersma, V. R.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2018-10-09
- Volume
- 39
- Issue
- 2
- Pages
- 517-560
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2897728813
- Cited by
- 199
- References
- 69
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.